Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Regulation of skin γδ T cell proliferation by glucose is associated with decreased STAT5B phosphorylation. by Kristen R. Taylor (246328)

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Hypoxia decreases expression of AQP5 protein and mRNA levels in MLE-12 cells. by Jitesh D. Kawedia (384551)

Tim-3 deficiency enhances the levels of proinflammatory cytokines and decreases the parasite burden. by Houbao Qi (11996039)

Decreased expression of 5-HT_2A receptors but not of PSD-95 in spinal cord of carrageenan-injected rats. by Anne-Sophie Wattiez (460341)

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

I348T increases H77 entry dependency on SR-BI, while T385P decreases H77 entry dependency on SR-BI. by Christina Holmboe Olesen (11154333)

FABP5 down regulation increases inflammation but decreases innate immunity in primary NHBE cells. by Fabienne Gally (260470)

“…<p><b>A.</b> CS exposure increases <i>P. aeruginosa</i> colony forming units (CFU) on FABP5 knocked down primary NHBE cells. …”

Time-dependent decreases in beclin-1 (A), Atg5 (B), and SIRT1 (C) protein expression in N2a cells exposed to exogenous Aβ1–42 (10μ μM). by Hye Rin Lee (616252)